FDgard®

FDgard® is the #1 gastroenterologist recommended⁴ medical food for the dietary management of Functional Dyspepsia (meal triggered indigestion). FDgard® utilizes breakthrough science via SST® (Site-Specific Targeting) to deliver caraway oil and l-Menthol quickly and reliably to the upper belly, effectively managing the symptoms of meal triggered indigestion.

FDgard® - The PreMeal Companion⁵

• FDgard® can be used for daily and proactive gut-health support⁶
• 8 in 10 patients reported symptom relief from meal triggered indigestion within 2 hours⁷
• FDgard® is gluten and lactose free

Suggested Use: Usual adult dosage⁸: two capsules, two times a day. Take 30-60 minutes before meal(s) with water. Do not exceed six capsules per day. Swallow capsules whole or open capsules and mix contents with applesauce. Do not chew.

Warning: USE UNDER MEDICAL SUPERVISION. Consult with a physician for use in children.

¹Among gastroenterologists who recommended herbal products for FD. IQVIA ProVoice survey (June 2019).
²With no known organic/diagnosed cause
³Based on FDREST™, a randomized, placebo-controlled trial of FDgard. Approved after peer review and then published in Clin Transl Gastroenteral 2019; 10(4)
⁴Among gastroenterologists who recommended herbal products for FD. IQVIA ProVoice survey (June 2019).
⁵Based on FDREST™, a randomized, placebo-controlled trial of FDgard. Approved after peer review and then published in Clin Transl Gastroenteral 2019; 10(4)
^{6 7}Chey WD, Lacy BE, Cash BD, Epstein M, et al. A Novel, Duodenal-Release Formulation of a Combination of Caraway Oil and L-Menthol for the Treatment of Functional Dyspepsia: A Randomized Controlled Trial. Clin Transl Gastroenterol. 2019;10(4) (FDRESTTM, Functional Dyspepsia Response Evaluation and Safety Trial)
⁸Based on FDREST™, a randomized, placebo-controlled trial of 100 FD patients. Patients taking FDgard experienced a statistically significant reduction versus placebo in postprandial distress syndrome (PDS) (p=0.004) and a near-significant reduction in epigastric pain syndrome (EPS) (p=0.07). Peer-reviewed and published in Clinical and Translational Gastroenterology 2019 10(4), Oral presentation by Dr. William Chey MD, FACG, AGAF, FACP, RFF, University of Michigan. In a real-world patient-reported outcomes trial, FDACT™, showed FDgard efficacy in the first hour. Presented at American College of Gastroenterology Annual Conference 2017; Orlando, FL.